311 related articles for article (PubMed ID: 26560853)
1. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C
Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853
[TBL] [Abstract][Full Text] [Related]
2. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer.
Liu L; Teng J; Zhang L; Cong P; Yao Y; Sun G; Liu Z; Yu T; Liu M
Biomed Res Int; 2017; 2017():2013989. PubMed ID: 28607926
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
Yang-Chun F; Min F; Di Z; Yan-Chun H
Medicine (Baltimore); 2016 May; 95(18):e3568. PubMed ID: 27149479
[TBL] [Abstract][Full Text] [Related]
4. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
5. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
6. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications for pro-GRP in small cell lung cancer. A single center experience.
Cavalieri S; Morelli D; Martinetti A; Galli G; Nichetti F; de Braud F; Platania M
Int J Biol Markers; 2018 Jan; 33(1):55-61. PubMed ID: 28967066
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
10. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
11. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
Yang Q; Zhang P; Wu R; Lu K; Zhou H
Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
[TBL] [Abstract][Full Text] [Related]
12. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
13. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
14. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
Zhao T; Mao G; Chen M
Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
[TBL] [Abstract][Full Text] [Related]
15. The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.
Wang Y; Wang Z; Ding Y; Sun F; Ding X
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2405-2407. PubMed ID: 31450913
[TBL] [Abstract][Full Text] [Related]
16. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
17. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Significance of Tumor Marker Detection in Patients
with Advanced Squamous Cell Carcimoma of the Lung].
Liang P; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):641-647. PubMed ID: 27760591
[TBL] [Abstract][Full Text] [Related]
20. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]